세계의 위장용 OTC 의약품 시장 : 약제 클래스별, 적응증별, 최종 사용자별, 지역별(2024-2032년)

The global gastrointestinal OTC drugs market size reached US$ 42.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 60.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4% during 2024-2032. The rising prevalence of gastrointestinal disorders, increasing awareness among the masses regarding digestive health, and the recent development of advanced formulations represent some of the key factors driving the market.

Gastrointestinal over-the-counter (OTC) drugs refer to non-prescription medications that alleviate gastrointestinal symptoms and promote overall digestive wellness. It includes laxatives, antacids, H2 blockers, proton pump inhibitors (PPIs), anti-emetics, bowel anti-inflammatory, and anti-diarrheal medications. Gastrointestinal OTC drugs are widely used to treat indigestion, constipation, heartburn, diarrhea, motion sickness, acid reflux, nausea, irritable bowel syndrome (IBS), and abdominal pain. It is a cost-effective, convenient, and easily accessible product that provides immediate relief, enhances patient comfort, and allows self-management. Gastrointestinal OTC drugs also aid in improving gut health, restoring beneficial bacteria, preventing future complications, and minimizing the severity of various symptoms, such as pain, bloating, abdominal discomfort, and vomiting.

Gastrointestinal OTC Drugs Market Trends:

The rising prevalence of gastrointestinal disorders due to sedentary lifestyles and unhealthy eating habits is one of the key factors providing a thrust to the market growth. Gastrointestinal OTC drugs are widely used to treat infections, dyspepsia, acute diarrhea, heartburn, gastroesophageal reflux disease (GERD), constipation, bloating, and morning sickness. Furthermore, the increasing product applications to improve digestion, promote gut health, and ensure proper breakdown and absorption of nutrients, owing to the growing awareness among the masses regarding digestive health, is providing an impetus to the market growth. In line with this, the emerging trends of self-care and consumer empowerment to manage well-being and prevent future health complications are acting as another growth-inducing factor. Additionally, the recent development of advanced formulations, such as effervescent tablets, liquids, suspensions, film strips, and chewable products, which enhances the effectiveness of the drugs, increases absorption, and reduces the frequency of dosing, is positively influencing the market growth. Besides this, the introduction of convenient and travel-friendly packaging, such as blister packs, resealable pouches, and single-dose packets, is propelling the market growth. Apart from this, the rising consumer preference for non-invasive treatments is facilitating product demand to manage common digestive issues and provide immediate relief. Moreover, aggressive promotional and branding campaigns by several manufacturers through television (TV) commercials, social media, influencer marketing, and celebrity endorsement is strengthening the market growth. Other factors, including the rising geriatric populations, increasing expenditure capacities of consumers, and easy availability of products across e-commerce platforms, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global gastrointestinal OTC drugs market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug class, indication, and end user.

Drug Class Insights:

Laxatives

Gastrointestinal Cancer Treatments

Gastric Acid Reducers

Anti-Diarrheal

Proton Pump Inhibitors

H2 Inhibitors

Gastric Acid Neutralizers

Bowel Anti-Inflammatory

Anti-Emetics

The report has provided a detailed breakup and analysis of the gastrointestinal OTC drugs market based on the drug class. This includes laxatives, gastrointestinal cancer treatments, gastric acid reducers, anti-diarrheal, proton pump inhibitors, H2 inhibitors, gastric acid neutralizers, bowel anti-inflammatory, and anti-emetics.

Indication Insights:

Gastroesophageal Reflux Disease (GERD) or Heartburn

Constipation

Diarrhea

Motion Sickness

Others

A detailed breakup and analysis of the gastrointestinal OTC drugs market based on the indication has also been provided in the report. This includes gastroesophageal reflux disease (GERD) or heartburn, constipation, diarrhea, motion sickness, and others.

End User Insights:

Hospitals

Clinics

Others

A detailed breakup and analysis of the gastrointestinal OTC drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and others.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for gastrointestinal OTC drugs. Some of the factors driving the North America gastrointestinal OTC drugs market included the rising prevalence of gastrointestinal disorders, increasing awareness among the masses, and various product innovations.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global gastrointestinal OTC drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Boehringer Ingelheim GmbH, Johnson & Johnson, Prestige Consumer Healthcare Inc., Purdue Pharma L.P, Sanofi, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• 1. How big is the global gastrointestinal OTC drugs market?
• 2. What is the expected growth rate of the global gastrointestinal OTC drugs market during 2024-2032?
• 3. What are the key factors driving the global gastrointestinal OTC drugs market?
• 4. What has been the impact of COVID-19 on the global gastrointestinal OTC drugs market?
• 5. What are the key regions in the global gastrointestinal OTC drugs market?
• 6. Who are the key players/companies in the global gastrointestinal OTC drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Gastrointestinal OTC Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Laxatives
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Gastrointestinal Cancer Treatments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Gastric Acid Reducers
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Anti-Diarrheal
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Proton Pump Inhibitors
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 H2 Inhibitors
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Gastric Acid Neutralizers
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Bowel Anti-Inflammatory
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast
• 6.9 Anti-Emetics
  • 6.9.1 Market Trends
  • 6.9.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Gastroesophageal Reflux Disease (GERD) or Heartburn
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Constipation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Diarrhea
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Motion Sickness
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Boehringer Ingelheim GmbH
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 SWOT Analysis
  • 14.3.2 Johnson & Johnson
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Prestige Consumer Healthcare Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Purdue Pharma L.P
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Sanofi
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Zydus Lifesciences Limited
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.